Sarepta Therapeutics appoints Catherine Stehman-Breen as CMO
Dr. Stehman-Breen joins Sarepta after having served as vice president, clinical development and regulatory affairs at Regeneron Pharmaceuticals since 2015, initially as head, pain therapeutic area, and subsequently as head, clinical project management and operations.
From 2003 to 2015, Dr. Stehman-Breen held senior leadership roles at Amgen including vice president, global development, leading the neuroscience, nephrology and bone therapeutic areas.
Dr. Stehman-Breen earned her M.D. from the University of Chicago in 1990.
She conducted her residency and fellowship training at the University of Washington, where she also received a Master of Science degree in Epidemiology in 1996.
Dr. Stehman-Breen spent six years as a faculty member in the Division of Nephrology at the University of Washington from 1997 to 2003, where her primary responsibilities included managing the Clinical Research Training Program and the development of the Epidemiology and Clinical Trials Research Program.
Her research focused on bone and cardiovascular disease in kidney disease patients.
Dr. Stehman-Breen was also active in a variety of national programs including serving as the Chair for USRDS NIDDK External Expert Panel and a reviewer for several journals. ■
LATEST MOVES FROM Massachusetts
- DentaQuest appoints Alison Corcoran as CMO
- RXI Pharma names Gerrit Dispersyn chief development officer
- resTORbio appoints Joan Mannick as CMO
- C&W Services appoints Mike Losier as director
- Charles River Associates appoints Robert A. Whitman to board
More inside POST
TUI stays at its 10% growth guidance Earnings